<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04523350</url>
  </required_header>
  <id_info>
    <org_study_id>INY-P-20-001</org_study_id>
    <nct_id>NCT04523350</nct_id>
  </id_info>
  <brief_title>Instylla HES Hypervascular Tumor Pivotal Study</brief_title>
  <official_title>Randomized Multi-Center, Subject and Evaluator Blinded, Parallel-Group Study to Evaluate the Safety and Effectiveness of the Instylla Hydrogel Embolic System (HES) Compared With Standard of Care Transcatheter Arterial Embolization (TAE) / Transcatheter Arterial Chemoembolization (cTACE) for Vascular Occlusion of Hypervascular Tumors; A Pivotal Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instylla, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instylla, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine whether Instylla HES has the ability to effectively embolize targeted arterial&#xD;
      segments of hypervascular tumors as well as standard of care (SOC) transarterial&#xD;
      embolization/conventional transarterial chemoembolization, while resulting in an acceptable&#xD;
      risk of device and procedure-related serious adverse events.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 4, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Effectiveness Endpoint: Delivery of the embolic agent to the index tumor feeding vessel with stasis of flow as determined by an independent radiologist via comparison of the pre and final post procedure images</measure>
    <time_frame>Immediately post-embolization procedure</time_frame>
    <description>Stasis of flow defined as absence of contrast flow within the targeted tumor feeding vessel</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Safety Endpoint: Freedom from major adverse events through 30 days post-index procedure</measure>
    <time_frame>30 days post-embolization procedure</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Hypervascular Tumors</condition>
  <arm_group>
    <arm_group_label>Instylla HES</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TAE or cTACE</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Instylla HES</intervention_name>
    <description>Instylla HES is a novel liquid embolic made of primarily water and polyethylene glycol (PEG)</description>
    <arm_group_label>Instylla HES</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>TAE or cTACE</intervention_name>
    <description>Bland TAE or cTACE</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subjects age ≥ 22 years old&#xD;
&#xD;
          -  Subjects with confirmed finding of hypervascular tumor on CT and/or MRI for whom&#xD;
             TAE/TACE is medically indicated&#xD;
&#xD;
          -  ECOG PS of 0-2 (PS 0-1 for metastatic disease)&#xD;
&#xD;
          -  Expected life expectancy ≥ 6 months after Index embolization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Embolization for lesions other than hypervascular tumors such as arteriovenous&#xD;
             malformations&#xD;
&#xD;
          -  Undergoing radioembolization or DEB-TACE for Index Procedure&#xD;
&#xD;
          -  Prior radioembolization of the target tumor lesion/vascular bed&#xD;
&#xD;
          -  For subjects with HCC or undergoing embolization to the liver: Child-Pugh Class C or&#xD;
             presence of complete portal vein thrombosis&#xD;
&#xD;
          -  Tumor lesions &gt;8cm in diameter (in one direction) or &gt;50% tumor volume burden of the&#xD;
             target organ&#xD;
&#xD;
          -  Any contraindication to arteriography or embolization protocol&#xD;
&#xD;
          -  Pregnant or breast-feeding or females planning on becoming pregnant within the next 3&#xD;
             months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chelsea Reinhold</last_name>
    <phone>781-209-6516</phone>
    <email>chelsear@instylla.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Brooke Mastrorio</last_name>
    <phone>781-790-4863</phone>
    <email>brookem@instylla.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Alfred Health</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerard Goh</last_name>
    </contact>
    <contact_backup>
      <last_name>Helen Kavnoudias</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 17, 2020</study_first_submitted>
  <study_first_submitted_qc>August 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2020</study_first_posted>
  <last_update_submitted>February 9, 2021</last_update_submitted>
  <last_update_submitted_qc>February 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

